Lichen Sclerosus (Investigational Adjunct)
Highly investigational adjunct for refractory anogenital lichen sclerosus; no RCT evidence; potent topical corticosteroid (clobetasol) remains standard of care.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for lichen sclerosus. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for lichen sclerosus is investigational.
- Какие доказательства существуют?
- Tier C (investigational). Only case reports; there are no randomized controlled trials. Evidence-based therapy for lichen sclerosus is ultra-potent topical corticosteroid (clobetasol propionate 0.05% once daily for 3 months, then maintenance) per AAD/BSGE guidelines. Topical calcineurin inhibitors as steroid-sparing. Vulvar disease requires gynecologic monitoring for squamous cell carcinoma risk (3-5 percent lifetime).
- Основные риски
- Bleeding from bite sites for 6 to 24 hours after detachment
- Worsening of fragile lichen sclerosus skin with trauma
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Triggering of new lichen sclerosus lesions at bite sites (Koebner phenomenon)
- Scarring or distortion in fragile genital tissue
- Delay of clobetasol therapy and gynecologic SCC monitoring
- Risk of missed early squamous cell carcinoma in untreated disease
- Кому не следует это рассматривать
- Patients with vulvar lichen sclerosus (gynecologic specialty care required)
- Patients with penile lichen sclerosus (urology referral)
- Patients with suspected squamous cell carcinoma (biopsy mandatory)
- Patients with active erosions, ulceration, or bleeding lesions
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients who have not used clobetasol 0.05% consistently for 3 months
- О чём спросить врача
- Has the diagnosis been confirmed by biopsy?
- Have I been screened for squamous cell carcinoma risk?
- Have I used clobetasol propionate 0.05% as directed for 3 months?
- Am I being monitored by a gynecologist or urologist for genital disease?
- What evidence specifically supports leech therapy for lichen sclerosus?
- Are leeches from an FDA-registered supplier and used only once?
- What is the cost and is it covered by insurance? (typically not covered)
- Когда срочно обратиться за медицинской помощью
- New ulceration, persistent erosion, or new firm lump at any lichen sclerosus site (rule out SCC)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Severe genital pain, bleeding, or urinary obstruction
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
Что это НЕ означает
- This is NOT FDA-cleared for lichen sclerosus.
- Case reports do NOT establish efficacy versus clobetasol 0.05%, the gold-standard treatment.
- It does NOT mean genital lichen sclerosus is appropriate for hirudotherapy — gynecologic or urologic specialty care is essential.
- It does NOT substitute for SCC screening — lichen sclerosus has a 3-5 percent lifetime SCC risk.
- It does NOT mean leech application is safe on fragile, atrophic, or eroded skin.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- dermatological
- ICD-10
- L90.0
- Safety tier
- high
Evidence Summary
Lichen sclerosus is a chronic inflammatory dermatosis with sclerotic dermal change and a risk of squamous cell carcinoma in long-standing untreated disease. Standard of care per BAD and AAD guidance is an ultra-potent topical corticosteroid (clobetasol propionate 0.05%) with long-term maintenance, plus regular surveillance. No controlled clinical trial of leech therapy for lichen sclerosus has been published; its use is investigational and mechanistic only. Direct anogenital application is contraindicated due to mucosal anatomy, infection risk, and lack of evidence. Patients must remain under dermatology follow-up for malignancy surveillance regardless of any adjunctive therapy. Evidence is grade D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Michalsen A (2007)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Anogenital placement of any kind
- Active vulvar or penile intraepithelial neoplasia
- Suspected squamous cell carcinoma in any lichen sclerosus plaque
- Discontinuation of prescribed topical corticosteroid maintenance
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.